Brukinsa (zanubrutinib) is a BTK (Bruton's tyrosine kinase) inhibitor, meaning it works by blocking a protein that signals cancer cells to grow. It's taken as a pill once or twice a day.
Over time, it has received FDA approval for several types of lymphoma, including:
- Mantle cell lymphoma (MCL) — after at least one Show Full Answer
Brukinsa (zanubrutinib) is a BTK (Bruton's tyrosine kinase) inhibitor, meaning it works by blocking a protein that signals cancer cells to grow. It's taken as a pill once or twice a day.
Over time, it has received FDA approval for several types of lymphoma, including:
- Mantle cell lymphoma (MCL) — after at least one prior treatment
- Waldenström's macroglobulinemia (WM)
- Marginal zone lymphoma (MZL) — relapsed or refractory, after at least one anti-CD20-based treatment
- Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
- Relapsed or refractory follicular lymphoma — in combination with obinutuzumab, after at least two prior treatments As with any medication, it's worth knowing the potential side effects. Common ones include:
- Anemia
- Neutropenia (low white blood cell count)
- Rash
- Bruising
- Diarrhea
- Cough
There are also some rarer but more serious risks, such as bleeding, infections, irregular heartbeat, liver damage, and a small chance of secondary cancers. It's also not recommended during pregnancy.
Always speak with your doctor about whether Brukinsa is appropriate for your specific situation.
July 22
Join
Your Privacy Choices
